This Article Full Text Full Text (PDF) Correction (v67,p7937) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scardino, A. Articles by Kosmatopoulos, K. Search for Related Content PubMed PubMed Citation Articles by Scardino, A. Articles by Kosmatopoulos, K.

A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge

¹ Institut National de la Santé et de la Recherche Médicale U753, Institut Gustave Roussy, Villejuif, France; ² Dipartimento di Medicina Sperimentale, Università di Roma "La Sapienza"; ³ Dipartimento di Medicina Sperimentale e Scienze Biochimiche, Università di Tor Vergata; ⁴ Centro Ricerca Sperimentale, Istituto Tumori Regina Elena, Rome, Italy; ⁵ Divisione di Oncologia Medica, Facoltà di Medicina, Università di Siena, Siena, Italy; ⁶ Academic Division of Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom; and ⁷ Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France

Requests for reprints: Antonio Scardino, Università di Roma "La Sapienza," Rome, Italy. Phone: 39-06-537-4342; Fax: 39-06-499-03615; E-mail: antoscardo{at}yahoo.it.

A cDNA vaccine (pVax1/pet-neu) was designed to encode 12 different Her-2/ErbB-2–derived, HLA-A*0201–restricted dominant and high-affinity heteroclitic cryptic epitopes. Vaccination with pVax1/pet-neu triggered multiple and ErbB-2–specific CTL responses in HLA-A*0201 transgenic HHD mice and in HLA-A*0201 healthy donors in vitro. Human and murine CTL specific for each one of the 12 ErbB-2 peptides recognized in vitro both human and murine tumor cells overexpressing endogenous ErbB-2. Furthermore, vaccination of HHD mice with pVax1/pet-neu significantly delayed the in vivo growth of challenged ErbB-2–expressing tumor (EL4/HHD/neu murine thymoma) more actively when compared with vaccination with the empty vector (pVax1) or vehicle alone. These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2–specific antitumor responses against dominant and cryptic multiple epitopes. [Cancer Res 2007;67(14):7028–36]

This article has been cited by other articles:

				Correction: Polyepitope DNA Vaccine and Tumor Challenge Cancer Res., August 15, 2007; 67(16): 7937 - 7937. [Full Text] [PDF]